ID   DU-145 R
AC   CVCL_4Y36
DR   cancercelllines; CVCL_4Y36
DR   Wikidata; Q54831571
RX   PubMed=21982118;
CC   Population: Caucasian.
CC   Selected for resistance to: ChEBI; CHEBI:4672; Docetaxel anhydrous (Taxotere).
CC   Sequence variation: Mutation; HGNC; 1787; CDKN2A; Simple; p.Asp84Tyr (c.250G>T) (p.Arg98Leu, c.293G>T); ClinVar=VCV000376306; Zygosity=Homozygous (from parent cell line).
CC   Sequence variation: Mutation; HGNC; 9884; RB1; Simple; p.Lys715Ter (c.2143A>T); ClinVar=VCV001786615; Zygosity=Homozygous (from parent cell line).
CC   Sequence variation: Mutation; HGNC; 11389; STK11; Simple; p.Lys178fs*86 (c.532_536delAAGCC); Zygosity=Homozygous (from parent cell line).
CC   Sequence variation: Mutation; HGNC; 11998; TP53; Simple; p.Pro223Leu (c.668C>T); ClinVar=VCV000234214; Zygosity=Heterozygous (from parent cell line).
CC   Sequence variation: Mutation; HGNC; 11998; TP53; Simple; p.Val274Phe (c.820G>T); ClinVar=VCV000376674; Zygosity=Heterozygous (from parent cell line).
CC   Derived from site: Metastatic; Brain; UBERON=UBERON_0000955.
DI   NCIt; C4863; Prostate carcinoma
OX   NCBI_TaxID=9606; ! Homo sapiens (Human)
HI   CVCL_0105 ! DU145
SX   Male
AG   69Y
CA   Cancer cell line
DT   Created: 14-12-15; Last updated: 05-10-23; Version: 14
//
RX   PubMed=21982118; DOI=10.1186/1476-4598-10-126;
RA   O'Neill A.J., Prencipe M., Dowling C., Fan Y., Mulrane L.,
RA   Gallagher W.M., O'Connor D., O'Connor R., Devery A.M., Corcoran C.,
RA   Rani S., O'Driscoll L., Fitzpatrick J.M., Watson R.W.G.;
RT   "Characterisation and manipulation of docetaxel resistant prostate
RT   cancer cell lines.";
RL   Mol. Cancer 10:126.1-126.13(2011).
//